Janssen-Cilag SpA, Via Buonarroti, 23, 20093 Cologno Monzese, Milan, Italy.
Expert Rev Gastroenterol Hepatol. 2012 Aug;6(4):423-35. doi: 10.1586/egh.12.18.
Proton pump inhibitors are widely used for the treatment of acid-related disorders. Rabeprazole is a potent and irreversible inhibitor of H(+)/K(+)-ATPase gastric pump, and it is indicated for the treatment of gastroesophageal reflux disease, Zollinger Ellison syndrome, duodenal and gastric ulcers and for the eradication of Helicobacter pylori in combination with antibiotics. Pharmacokinetic and pharmacodynamic data show that rabeprazole achieves a pronounced acid suppression from the first administration that is maintained with repeated use; this may translate into faster onset of symptom relief for patients, particularly suitable when the indication is for the on-demand long-term maintenance of gastroesophageal reflux disease. Due to its predominantly nonenzymatic metabolism, rabeprazole has a lower potential for drug-drug interactions. The objective of this article is to update efficacy and safety data of rabeprazole in the treatment of acid-related disorders, following a previous review dated 2008.
质子泵抑制剂被广泛用于治疗酸相关疾病。雷贝拉唑是一种强效且不可逆的 H(+)/K(+)-ATP 酶胃泵抑制剂，用于治疗胃食管反流病、卓-艾综合征、十二指肠和胃溃疡，以及与抗生素联合根除幽门螺杆菌。药代动力学和药效学数据表明，雷贝拉唑从首次给药开始即能显著抑制胃酸分泌，并可通过重复用药维持；这可能会使患者更快地缓解症状，尤其适用于按需长期维持治疗胃食管反流病的情况。由于其主要通过非酶代谢，雷贝拉唑发生药物相互作用的潜力较低。本文旨在更新雷贝拉唑治疗酸相关疾病的疗效和安全性数据，此前的综述发表于 2008 年。
